Printer Friendly

Differences in Neuropathogenesis of Encephalitic California Serogroup Viruses.

The California serogroup (CSG) of orthobunyaviruses comprises a large group of closely related mosquitoborne, trisegmented, negative-sense RNA viruses in the family Peribunyaviridae of the order Bunyavirales. La Crosse virus (LACV), snowshoe hare virus (SSHV), Tahyna virus (TAHV), Jamestown Canyon virus (JCV), and Inkoo virus (INKV) are members of the CSG that have been reported to cause neurologic disease in humans. LACV, SSHV, TAHV, and INKV primarily cause neuroinvasive disease in children; however, the incidence differs for each virus (1-3). LACV is the leading cause of pediatric viral encephalitis in the United States, responsible for [approximately equal to] 50-100 reported cases per year. SSHV and TAHV only cause several reported cases of neuroinvasive disease annually (1,2,4-6), and TAHV disease most often manifests as influenza-like symptoms and only rarely leads to encephalitis (2,7). INKV has caused the fewest cases of human disease. However, several confirmed neuroinvasive cases have occurred in Finland, and children had more severe disease than adults (3). In contrast, JCV appears to preferentially cause neuroinvasive disease in adults, and several cases occur every year in the United States and Canada (1,8). Because the number of reported cases increased substantially in the 2010s, JCV is considered a potentially emerging arboviral disease (9).

The number of actual cases caused by these CSG viruses is likely underreported because of the difficulty of diagnosing these viral infections. Patients who do not seek medical treatment and those with less severe disease might not be included in case reports. All 5 viruses have high reported seroprevalence rates in endemic regions: [approximately equal to] 1%-27% for LACV, JCV, and SSHV; [approximately equal to] 24%-51% for INKV; and up to 80% for TAHV (1,2,10-12).

These CSG viruses have differing but overlapping geographic distributions (Figure 1, panel A). LACV, JCV, and SSHV are all found in the United States; JCV and SSHV extend into Canada; and SSHV extends into Russia (1,2,4,8,10,13-28). Although TAHV and INKV are primarily found in Europe, TAHV extends into Africa and Asia, and INKV is limited to northern Europe and Russia (2,3,12,29,34-36). These CSG viruses use a variety of mosquito vectors, primarily in the Aedes and Ochlerotatus genera, and mammalian host species, including small rodents (SSHV, LACV, and TAHV), hares (SSHV, TAHV, and INKV), and deer (JCV) (Figure 1, panel B) (1,2,12,22,29,31-33).

Despite their differing and widespread geographical distributions, the CSG viruses are genetically closely related. The large segment encodes the viral RNA-dependent RNA polymerase, the medium segment encodes 2 envelope glycoproteins and a nonstructural protein, and the small segment encodes the nucleocapsid and a second nonstructural protein (NSs), which in LACV is a type I interferon antagonist (37,38). Across all 3 segments, JCV and INKV are the most closely related to each other, with 84%-92.4% nucleotide identity, followed by LACV and SSHV with 79.4%-89.1% nucleotide identity (30). TAHV has [approximately equal to] 72.5%-84.7% nucleotide identity with LACV and SSHV and 69.2%-80.3% with JCV and INKV (30).

In mouse studies of LACV, weanling C57BL/6 mice were susceptible to neurologic disease after intraperitoneal inoculation, but adult mice were not, demonstrating age-dependent susceptibility to disease that mimics clinical disease in humans (39). Certain strains of TAHV, but not JCV, have been shown to cause neurologic disease in weanling Swiss Webster mice after intraperitoneal inoculation, although both viruses were capable of replicating in the brain after intracranial inoculation (40,41). In these studies, only weanling mice were used, and thus, age-dependent susceptibility was not evaluated.

Determining how LACV, SSHV, TAHV, JCV, and INKV differ in pathogenesis in animal and cell culture models could help explain their differing disease outcomes in humans. However, a direct comparison between these viruses in their ability to invade the central nervous system (CNS) and induce neuronal damage has not been investigated. In this study, we investigated age-related differences in pathogenesis of LACV, SSHV, TAHV, JCV, and INKV. We examined the ability of these viruses to enter the CNS and cause disease in mice and their ability to replicate in neurons and induce cell death in vitro.

Materials and Methods

Cells and Viruses

All cell culture reagents were from Gibco (http://www. biosciences.ie/gibco) unless otherwise specified. We maintained Vero cells in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum (Atlas Biologicals, https://atlasbio.com) and 1% penicillin/streptomycin solution; C6/36 cells in minimum essential medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 1x nonessential amino acids, and 1% penicillin/streptomycin; the neuroblastoma cell line SH-SY5Y (American Type Culture Collection [ATCC], https://www.atcc.org) in a 1:1 ratio of Eagle minimum essential medium (ATCC) and F12K (ATCC) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin; and H9 human embryonic stem cell-derived human neural stem cells (hNSCs; Gibco, https://www.fishersci.com) in KnockOut DMEM/F-12 supplemented with 1x GlutaMAX-I Supplement, 20 ng/mL basic fibroblast growth factor, 20 ng/mL epidermal growth factor, 2% StemPro neural supplement, and 1% penicillin/ streptomycin. We seeded hNSCs on plates or flasks treated with 20 g.g/mL fibronectin in Dulbecco phosphate-buffered saline for 1 h at 37[degrees]C. We passaged stocks of LACV (human 1978 strain), JCV (strain 61V2235), TAHV (strain 92 Bardos), SSHV (1976), and INKV (SW AR 83-161), all kindly provided by Stephen Whitehead (Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA), in Vero or C6/36 cells up to 3 times.

Inoculation of Mice

All mouse experiments were approved by the Rocky Mountain Laboratories Animal Care and Use Committee (Hamilton, Montana, USA) and performed in accordance with National Institutes of Health guidelines under protocol 2016-061-E. We used C57BL/6 mice for all experiments.

We inoculated weanlings at 21-23 days of age, adults at 6-8 weeks of age, and aged mice at 19-34 weeks of age. We diluted the viruses in phosphate-buffered saline (PBS). For intraperitoneal inoculations, we injected mice with [10.sup.5] or [10.sup.3] PFU of virus in a volume of 200 [micro]L. For intranasal inoculations, we inoculated mice with [10.sup.4] or [10.sup.2] PFU of virus in a volume of 20 [micro]L. We anesthetized mice with isoflurane before inoculation. After inoculation, we checked mice twice daily for clinical signs of neurologic disease, which primarily included ataxia, circling, limb paralysis and weakness, twitching, and seizures. Mice displaying signs of neurologic disease were perfused transcardially with 100 U/mL heparin saline before removal of tissues. We humanely euthanized mice that did not display any signs of neurologic disease by 30 days postinoculation (dpi).

RNA Isolation and Quantitative Reverse Transcription PCR

For RNA analysis, we flash-froze spleens and brain tissue from infected mice in liquid nitrogen, then stored them at -80[degrees]C. We performed mRNA analysis as previously described (42). We amplified viral RNA from mouse tissues using the following virus-specific primers: LACV forward (5'-ATTCTACCCGCTGACCATTG-3') and reverse (5'-GTGAGAGTGCCATAGCGTTG-3'), SSHV forward (5'-AGCATGATCAAAACGGAGGC-3') and reverse (5'-CATGCCAATCAGACACCAGC-3'), TAHV forward (5'-AGGTCCTACATTGCCGTTCA-3') and reverse (5'-TGGTCTACAGGTGCTAGCTC-3'), JCV forward (5'-'TATGGTTCCCCGGTAGTGTG-3') and reverse (5'-TAACATGGTGCTTCTCGTGC-3'), and INKV forward (5'-AGTCCAAGATAAAGCCCCAGA-3') and reverse (5'-TCATGTTAGCCTGGCATCCA-3'). We subjected primer sequences to BLAST analysis (https:// blast.ncbi.nlm.nih.gov/Blast.cgi) and tested each primer set on RNA from brains of mice infected with the 5 CSG viruses that had neurologic disease to verify virus-specific amplification by each primer set.

Immunohistochemistry

For immunohistochemistry studies, we transcardially perfused mice, removed tissues, and placed them in 10% neutral buffered formalin. After fixation, we cryoprotected tissues in 30% sucrose in PBS, embedded them in Tissue-Tek O.C.T. Compound (Sakura, https://www.sakura.eu) and froze them on dry ice; then, 10-[micro]m sections were cut on a cryostat and mounted on slides. We washed sections with PBS and blocked for 30 minutes in blocking buffer (PBS with 5% normal donkey serum, 0.1% triton-X, and 0.3 M glycine). We diluted the primary antibody against viral antigens (inhouse polyclonal antibody raised in rabbits in response to LACV infection, 1:100) and microtubule-associated protein 2 (mouse monoclonal antibody MAB3418, 1:200; Millipore, http://www.emdmillipore.com) in blocking buffer, applied these solutions to tissues, and incubated them overnight at 4[degrees]C. We washed tissue sections with PBS and incubated for 1 hour at room temperature with donkey anti-rabbit Alexa Fluor 647 (1:1,000, Life Technologies, https://www.thermofisher.com) and donkey anti-mouse Alexa Fluor 594 (1:500, Life Technologies). After washing sections again with PBS, we stained with Hoechst (1:1,000) and mounted on slides with ProLong Gold (Invitrogen, https://www.thermofisher. com). We imaged entire brain sections using the Zeiss Axio Scan.Z1 (https://www.zeiss.com) with the 40x objective lens. We acquired high-resolution images on the Zeiss 710 laser scanning microscope with the 63 x objective and processed images in Imaris version 8.4.1 (https://imaris.oxinst. com) or Fiji (http://fiji.sc).

Cytotoxicity Assays

We coated 96-well plates with fibronectin as previously described and seeded 5 x 104 SH-SY5Y cells or 2 x 104 hNSCs per well. The next day, cells were inoculated with each virus in triplicate at multiplicities of infection (MOIs) of 0.1 and 0.01 for SH-SY5Y cells and 0.01 and 0.001 for hNSCs. We added Cytotox Green (Essen Bioscience, https://www.essenbioscience.com) for a final well volume of 100 p.L and a final concentration of 250 nM. Cells were then imaged with an IncuCyte (Essen Bioscience) by taking 3 images per well with the 20x objective every 3 hours during a 97-hour time course. We measured confluence and fluorescent intensity using IncuCyte S3 software. We performed all statistical analyses using Prism 7.0c (https://www. graphpad.com).

Replication Kinetics

We plated and inoculated cells as described in the previous section, except that plates seeded with SHSY5Y cells were not treated with fibronectin. We collected supernatants at 1, 6, 12, 24, 48, 72, and 96 hours postinoculation. We determined virus titers of supernatants by plaque assay using Vero cells as described previously (43). We counted LACV, TAHV, and JCV plaques at 5 dpi and SSHV and INKV plaques at 3 dpi. We performed all statistical analyses using Prism 7.0c (https://www.graphpad.com).

Results

Assessment of Neuroinvasive Disease in Mice after Intraperitoneal Inoculation with CSG Viruses

To determine if these 5 CSG viruses differed in their ability to enter the CNS and cause neurologic disease (i.e., neuroinvasive disease), C57BL/6 mice were inoculated intraperitoneally with a high dose ([10.sup.5] PFU) of each virus. Because previous studies of LACV infection showed clear age-dependent differences in disease susceptibility between weanling and adult mice, we inoculated weanling, adult, and aged mice with each virus and followed them for the development of clinical signs of neurologic disease. None of the viruses induced neuroinvasive disease in adult or aged mice after intraperitoneal inoculation (data not shown). However, neuroinvasive disease developed by 5-6 dpi in all weanling mice inoculated with [10.sup.5] PFU of LACV (Figure 2, panel A), consistent with previous reports (39,44). SSHV induced neuroinvasive disease in [approximately equal to] 70% of weanling mice and TAHV in [approximately equal to] 80% of weanling mice. Neurologic signs were primarily observed at 6-7 dpi for SSHV and 5-6 dpi for TAHV. Neurologic signs were similar for LACV, SSHV, and TAHV and included ataxia, circling, limb paralysis and weakness, twitching, and seizures. JCV and INKV did not induce neuroinvasive disease in any weanling mice.

In previous studies with LACV, nearly 100% of weanling mice were susceptible to neuroinvasive disease after intraperitoneal inoculation at a dose of [10.sup.3] PFU (39). To determine if TAHV and SSHV also maintain their pathogenicity at this low dose, we inoculated weanling mice intraperitoneally with 103 PFU of LACV, SSHV, or TAHV. JCV and INKV were not included in this experiment because they did not induce neuroinvasive disease at the high dose. Consistent with previous studies, [10.sup.3] PFU of LACV caused disease in 100% of mice but with a slight delay in the onset of neurologic signs compared with the [10.sup.5] PFU dose (Figure 2, panel B). At the low dose, SSHV induced disease in a similar percentage of mice as the high dose, whereas TAHV caused disease in only 1 of 9 mice at the low dose (Figure 2, panel B).

All weanling mice with neurologic disease had detectable viral RNA in the brain, whereas weanling, adult, and aged mice without neurologic disease had no detectable virus in the brain compared with mock controls (Figure 2, panels C, D; data not shown). Regardless of disease outcome, mice had little to no detectable viral RNA in the spleen (Figure 2, panels E, F; data not shown), suggesting clearance of virus from the periphery.

Overall, these results indicate that LACV, SSHV, and TAHV can induce neuroinvasive disease in weanling mice after intraperitoneal inoculation, whereas JCV and INKV cannot. None of the CSG viruses caused neurologic signs in adult or aged mice after intraperitoneal inoculation, suggesting an age-related susceptibility of mice to LACV-, SSHV-, and TAHV-induced neuroinvasive disease.

Assessment of Neurovirulence of CSG Viruses after Intranasal Inoculation of Mice

The inability of a virus to cause neuroinvasive disease after intraperitoneal inoculation could be due to a lack of virus replication in the periphery or an inability of the virus to gain access to the CNS. These barriers can be bypassed by intracranial or intranasal inoculation. For example, LACV is not neuroinvasive in adult mice after intraperitoneal inoculation but does cause disease in adult mice when inoculated intracranially or intranasally (39,44,45). Because none of these CSG viruses caused disease in older mice after intraperitoneal inoculation, adult and aged mice were inoculated intranasally with each virus to determine if they were neurovirulent (i.e., could replicate in the brain) and neuropathogenic (i.e., could cause disease in the brain) after a more direct inoculation route and to determine if neuropathogenesis was restricted by age. Because of the low stock concentration of some viruses, we could not inoculate mice with [10.sup.5] PFU intranasally; therefore, we used a high dose of [10.sup.4] PFU and a low dose of [10.sup.2] PFU. At a dose of [10.sup.4] PFU per mouse, all viruses except INKV induced neurologic disease in nearly all adult and aged mice (Figure 3, panels A, C). INKV was less neuropathogenic than the other CSG viruses, inducing disease in only 1 of 6 adult mice and 2 of 7 aged mice. Compared with the high dose, the low dose induced neurologic disease in a reduced percentage of mice for all viruses, except LACV in aged mice (Figure 3, panels E,G). Viral RNA was readily detectable in the brains (Figure 3, panels B, D, F, H) but not spleens (data not shown) of all mice with neurologic disease.

Because INKV induced limited disease in adult mice, we inoculated weanling mice intranasally with INKV to determine if neuropathogenicity was age dependent. Neurologic disease developed in 3 (60%) of 5 mice and was associated with viral RNA in the brain (Figure 3, panels A, I). Thus, with a high dose and direct intranasal route to the CNS, INKV was more neuropathogenic in young mice than in adults (Figure 3, panels B, J).

Next, we examined the distribution of the CSG viruses in the brain using immunohistochemistry. In mice inoculated intranasally with 104 PFU of LACV, SSHV, TAHV, or JCV that had neurologic disease, virus was widespread throughout the brains regardless of the day after inoculation or severity of neurologic disease (Figure 4, panels A, B). In contrast, the brains of adults and aged mice displaying neurologic disease after intranasal inoculation of INKV showed only small, sporadic patches of virus (Figure 4, panels A, B). All viruses co-localized with the neuronal marker microtubule-associated protein 2, indicating that all CSG viruses primarily infected neurons within the CNS (Figure 4, panel C). Overall, these results demonstrate that LACV, SSHV, TAHV, and JCV are neurovirulent in mice when inoculated intranasally, whereas INKV appears to be less neurovirulent and infects fewer neurons within the CNS.

Ability of CSG Viruses to Replicate in and Kill Neurons in vitro

The differences in pathogenicity among the CSG viruses observed in mice and humans could be related to differences in their ability to infect and kill neurons. Therefore, we analyzed the ability of these viruses to replicate in and kill neurons using the human neuroblastoma cell line SHSY5Y and hNSCs. We inoculated cells with each virus at MOIs predetermined to provide a sufficient time frame to measure virus replication before the onset of substantial cell death with LACV (MOIs of 0.1 and 0.01 for SH-SY5Y cells and MOIs of 0.01 and 0.001 for hNSCs). In SH-SY5Y cells, LACV, SSHV, and TAHV induced substantial cell death at both MOIs, whereas JCV and INKV induced little cell death (Figure 5, panels A, B, E, F). However, JCV and INKV replicated to similar titers as LACV (Table 1), albeit with a delay in replication (Table 1; Figure 5, panels I, J). In hNSCs, all 5 viruses induced cell death at both MOIs (Figure 5, panels C, D, G, H); however, LACV had a more pronounced cell death rate than the other viruses, indicating that LACV may be more neurotoxic to hNSCs than the other 4 CSG viruses, most notably INKV (Table 2; Figure 5, panels G, H). All viruses rapidly replicated to high titers at both MOIs in hNSCs; however, JCV appeared to replicate slower and reached a lower peak titer than the other CSG viruses (Table 2; Figure 5, panels K, L). All CSG viruses had significantly slower rates of growth in hNSCs with 1 or both MOIs compared with LACV (Table 2).

Together, these results suggest that LACV, SSHV, and TAHV are capable of replicating quickly to high titers in neurons and inducing substantial cell death. In contrast, INKV and JCV replicated more slowly but to similar titers. INKV and JCV also induced less cell death than the other CSG viruses, although the level of cell death varied by cell type. The lower cell death associated with INKV infection in vitro correlates with the low level of INKV infection within the CNS in vivo.

Discussion

In our study, the CSG viruses differed in pathogenesis both in mice and in vitro. Overall, LACV showed the highest neuropathogenicity and neurovirulence in vitro and in vivo, whereas INKV was the least pathogenic. These results appear to be consistent with disease patterns observed in humans, with LACV reported to cause the most neuroinvasive cases, and INKV only infrequent cases (3,4,14). Only LACV, TAHV, and SSHV were capable of causing neuroinvasive disease, a finding only observed in weanling mice. The lack of disease in adult animals is consistent with previous findings with LACV, where an age-dependent immune response in adult mice protects them from virus-induced neurologic disease (39,46).

LACV and SSHV maintained similar levels of neuroinvasiveness down to a dose of 103 PFU, whereas TAHV's ability to induce neuroinvasive disease was greatly diminished at this low dose (Figure 2, panels A, B). The difference in dose-dependent disease susceptibility suggests that TAHV might be less virulent than LACV or SSHV. The lower virulence of TAHV than LACV or SSHV correlates with the low number of TAHV-induced neuroinvasive cases in humans, despite TAHV's larger geographic distribution and higher rates of seroprevalence than LACV (1,2,4).

When the peripheral immune system was bypassed and adult and aged mice were inoculated intranasally, all viruses except INKV replicated extensively throughout the brain and caused neurologic disease (Figure 4). However, INKV did cause disease in a few adult and aged mice and 60% of weanling mice after intranasal inoculation, indicating INKV can be neuropathogenic under certain conditions, particularly in younger animals. These results are consistent with human case reports showing that INKV causes more severe disease in children than adults (3).

Less viral antigen was found in the brains of the 3 adult and aged INKV-inoculated mice that developed neurologic disease than in the brains from mice infected with the other CSG viruses (Figure 4). INKV induced less cell death than LACV in SH-SY5Y cells, suggesting that the lack of neuropathogenicity observed with INKV in vivo could be due to low levels of INKV-induced neuronal cell death. In addition, INKV also replicated slower than LACV in SH-SY5Y cells, suggesting the limited spread of INKV in the brains of mice might be due to inefficient replication of INKV in neurons. Further studies are needed to determine why INKV has a reduced ability to induce neuronal death compared with other CSG viruses.

In humans, JCV appears to be distinct from the other CSG viruses in that JCV preferentially causes neuroinvasive disease in adults rather than in children. Although we did not observe a similar age-dependent difference in neuroinvasion of JCV in mice, this virus did differ from the other CSG viruses. JCV (like INKV) was unable to invade the CNS, yet JCV (like LACV, SSHV, and TAHV) was highly neurovirulent in brains of mice when inoculated intranasally. However, the same high level of neurovirulence was not observed in vitro. In both SH-SY5Y cells and hNSCs, JCV induced less cell death and replicated slower than LACV. These findings suggest there might be underlying genetic differences or complexities in JCV pathogenesis not shared by any of the other CSGs.

Given that genetic variation exists within and between these encephalitic CSG viruses (30), additional differences in pathogenicity might exist for different isolates not tested in our studies. However, overall these results show that, despite being closely related, these CSG viruses differ substantially in their abilities to induce neurologic disease in mice and replicate in neurons in vitro and in vivo. Further characterization of the host and viral factors that contribute to the differences in CSG virus pathogenesis will help determine why INKV is less neurovirulent than the other CSG viruses and elucidate potential targets for CSG virus encephalitis therapies.

Acknowledgments

We thank Stephen Whitehead for providing the CSG viruses, Paul Policastro for assistance with SH-SY5Y cells and hNSC cultures, and Tyson Woods for LACV stock preparation and technical assistance. We thank Austin Athman and Ryan Kissinger for the preparation of Figure 1. We thank Leonard Evans, Stefano Boi, Emmie de Wit, and Carrie Long for critical review of the manuscript. We thank the staff of the Rocky Mountain Veterinary Branch, in particular Malea Higgins and Maarit Culbert, for excellent care of the animals used in this study.

This work was supported by the National Institutes of Allergy and Infectious Diseases Division of Intramural Research, National Institutes of Health.

Dr. Evans is a postdoctoral fellow in the Laboratory of Persistent Viral Diseases at Rocky Mountain Laboratories in Hamilton, Montana, USA. Her primary research interests are in comparative viral genetics and viral-host interactions.

References

(1.) Drebot MA. Emerging mosquito-borne bunyaviruses in Canada. Can Commun Dis Rep. 2015;41:117-23. http://dx.doi.org/ 10.14745/ccdr.v41i06a01

(2.) Hubalek Z. Mosquito-borne viruses in Europe. Parasitol Res. 2008; 103(Suppl 1):29-43. http://dx.doi.org/10.1007/s00436-008-1064-7

(3.) Putkuri N, Kantele A, Levanov L, Kivisto I, Brummer-Korvenkontio M, Vaheri A, et al. Acute human Inkoo and Chatanga virus infections, Finland. Emerg Infect Dis. 2016;22:810-7. http://dx.doi.org/10.3201/eid2205.151015

(4.) Centers for Disease Control and Prevention. La Crosse encephalitis. Epidemiology and geographic distribution. 2018 Jan 25 [cited 2018 May 22]. https://www.cdc.gov/lac/tech/epi.html

(5.) Gaensbauer JT, Lindsey NP, Messacar K, Staples JE, Fischer M. Neuroinvasive arboviral disease in the United States: 2003 to 2012. Pediatrics. 2014;134:e642-50. http://dx.doi.org/10.1542/ peds.2014-0498

(6.) Lau L, Wudel B, Kadkhoda K, Keynan Y. Snowshoe hare virus causing meningoencephalitis in a young adult from northern Manitoba, Canada. Open Forum Infect Dis. 2017;4:ofx150. http://dx.doi.org/10.1093/ofid/ofx150

(7.) Kilian P, Ruzek D, Danielova V, Hypsa V, Grubhoffer L. Nucleotide variability of Tahyna virus (Bunyaviridae, Orthobunyavirus) small (S) and medium (M) genomic segments in field strains differing in biological properties. Virus Res. 2010;149:119-23. http://dx.doi.org/10.1016/ j.virusres.2010.01.005

(8.) Pastula DM, Hoang Johnson DK, White JL, Dupuis AP II, Fischer M, Staples JE. Jamestown Canyon virus disease in the United States-2000-2013. Am J Trop Med Hyg. 2015;93:384-9. http://dx.doi.org/10.4269/ajtmh.15-0196

(9.) Pastula DM, Smith DE, Beckham JD, Tyler KL. Four emerging arboviral diseases in North America: Jamestown Canyon, Powassan, chikungunya, and Zika virus diseases. J Neurovirol. 2016;22:257-60. http://dx.doi.org/10.1007/s13365-016-0428-5

(10.) Kosoy O, Rabe I, Geissler A, Adjemian J, Panella A, Laven J, et al. Serological survey for antibodies to mosquito-borne bunyaviruses among US National Park Service and US Forest Service employees. Vector Borne Zoonotic Dis. 2016;16:191-8. http://dx.doi.org/10.1089/vbz.2015.1865

(11.) Monath TP, Nuckolls JG, Berall, Bauer H, Chappell WA, Coleman PH. Studies on California encephalitis in Minnesota. Am J Epidemiol. 1970;92:40-50. http://dx.doi.org/10.1093/ oxfordjournals.aje.a121178

(12.) Putkuri N, Vaheri A, Vapalahti O. Prevalence and protein specificity of human antibodies to Inkoo virus infection. Clin Vaccine Immunol. 2007;14:1555-62. http://dx.doi.org/10.1128/ CVI.00288-07

(13.) Walters LL, Tirrell SJ, Shope RE. Seroepidemiology of California and Bunyamwera serogroup (Bunyaviridae) virus infections in native populations of Alaska. Am J Trop Med Hyg. 1999;60: 806-21. http://dx.doi.org/10.4269/ajtmh.1999.60.806

(14.) Haddow AD, Odoi A. The incidence risk, clustering, and clinical presentation of La Crosse virus infections in the eastern United States, 2003-2007. PLoS One. 2009;4:e6145. http://dx.doi.org/ 10.1371/journal.pone.0006145

(15.) Clark GG, Crabbs CL, Watts DM, Bailey CL. An ecological study of Jamestown Canyon virus on the Delmarva Peninsula, with emphasis on its possible vector. J Med Entomol. 1986;23:588-99. http://dx.doi.org/10.1093/jmedent/23.6.588

(16.) Boromisa RD, Grimstad PR. Virus-vector-host relationships of Aedes stimulans and Jamestown Canyon virus in a northern Indiana enzootic focus. Am J Trop Med Hyg. 1986;35:1285-95. http://dx.doi.org/10.4269/ajtmh.1986.35.1285

(17.) Pinger RR, Rowley WA, Wong YW, Dorsey DC. Trivittatus virus infections in wild mammals and sentinel rabbits in central Iowa. Am J Trop Med Hyg. 1975;24:1006-9. http://dx.doi.org/10.4269/ ajtmh.1975.24.1006

(18.) Heard PB, Zhang MB, Grimstad PR. Isolation of Jamestown Canyon virus (California serogroup) from Aedes mosquitoes in an enzootic focus in Michigan. J Am Mosq Control Assoc. 1990; 6:461-8.

(19.) Anderson JF, Main AJ, Armstrong PM, Andreadis TG, Ferrandino FJ. Arboviruses in North Dakota, 2003-2006. Am J Trop Med Hyg. 2015;92:377-93. http://dx.doi.org/10.4269/ ajtmh.14-0291

(20.) McFarlane BL, Embil JA, Artsob H, Spence L, Rozee KR. Antibodies to the California group of arboviruses in the moose (Alces alces americana Clinton) population of Nova Scotia. Can J Microbiol. 1981;27:1219-23. http://dx.doi.org/10.1139/m81-187

(21.) Berry RL, Weigert BJL, Calisher CH, Parsons MA, Bear GT. Evidence for transovarial transmission of Jamestown Canyon virus in Ohio. Mosq News. 1977;37:494-6.

(22.) Issel CJ, Hoff GL, Trainer DO. Serologic evidence of infection of white-tailed deer in Texas with three California group arboviruses, (Jamestown Canyon, San Angelo, and Keystone). J Wildl Dis. 1973;9:245-8. http://dx.doi.org/10.7589/0090-3558-9.3.245

(23.) Tyers D, Zimmer J, Lewandowski K, Hennager S, Young J, Pappert R, et al. Serologic survey of snowshoe hares (Lepus americanus) in the Greater Yellowstone Area for brucellosis, tularemia, and snowshoe hare virus. J Wildl Dis. 2015;51:769-73. http://dx.doi.org/10.7589/2015-01-021

(24.) Campbell GL, Eldridge BF, Hardy JL, Reeves WC, Jessup DA, Presser SB. Prevalence of neutralizing antibodies against California and Bunyamwera serogroup viruses in deer from mountainous areas of California. Am J Trop Med Hyg. 1989;40:428-37. http://dx.doi.org/10.4269/ajtmh.1989.40.428

(25.) Eldridge BF, Calisher CH, Fryer JL, Bright L, Hobbs DJ. Serological evidence of California serogroup virus activity in Oregon. J Wildl Dis. 1987;23:199-204. http://dx.doi.org/10.7589/ 0090-3558-23.2.199

(26.) Issel CJ, Trainer DO, Thompson WH. Serologic evidence of infections of white-tailed deer in Wisconsin with three California group arboviruses (La Crosse, trivittatus, and Jamestown Canyon). Am J Trop Med Hyg. 1972;21:985-8. http://dx.doi.org/10.4269/ ajtmh.1972.21.985

(27.) Srihongse S, Grayson MA, Deibel R. California serogroup viruses in New York state: the role of subtypes in human infections. Am J Trop Med Hyg. 1984;33:1218-27. http://dx.doi.org/10.4269/ ajtmh.1984.33.1218

(28.) Walker ED, Grayson MA, Edman JD. Isolation of Jamestown Canyon and snowshoe hare viruses (California serogroup) from Aedes mosquitoes in western Massachusetts. J Am Mosq Control Assoc. 1993;9:131-4.

(29.) Jentes ES, Robinson J, Johnson BW, Conde I, Sakouvougui Y, Iverson J, et al. Acute arboviral infections in Guinea, West Africa, 2006. Am J Trop Med Hyg. 2010;83:388-94. http://dx.doi.org/10.4269/ajtmh.2010.09-0688

(30.) Hughes HR, Lanciotti RS, Blair CD, Lambert AJ. Full genomic characterization of California serogroup viruses, genus Orthobunyavirus, family Peribunyaviridae including phylogenetic relationships. Virology. 2017;512:201-10. http://dx.doi.org/ 10.1016/j.virol.2017.09.022

(31.) Pantuwatana S, Thompson WH, Watts DM, Hanson RP. Experimental infection of chipmunks and squirrels with La Crosse and trivittatus viruses and biological transmission of La Crosse virus by Aedes triseriatus. Am J Trop Med Hyg. 1972;21:476-81. http://dx.doi.org/10.4269/ajtmh.1972.21.476

(32.) Artsob H. Distribution of California serogroup viruses and virus infections in Canada. Prog Clin Biol Res. 1983;123:277-90.

(33.) Andreadis TG, Anderson JF, Armstrong PM, Main AJ. Isolations of Jamestown Canyon virus (Bunyaviridae: Orthobunyavirus) from field-collected mosquitoes (Diptera: Culicidae) in Connecticut, USA: a ten-year analysis, 1997-2006. Vector Borne Zoonotic Dis. 2008;8:175-88. http://dx.doi.org/10.1089/ vbz.2007.0169

(34.) Kunz C, Buckley SM, Casals J. Antibodies in man against Tahyna and Lumbo viruses determined by hemagglutination-inhibition and tissue-culture neutralization tests. Am J Trop Med Hyg. 1964;13:738-41. http://dx.doi.org/10.4269/ajtmh.1964.13.738

(35.) Sonnleitner ST, Lundstrom J, Baumgartner R, Simeoni J, Schennach H, Zelger R, et al. Investigations on California serogroup orthobunyaviruses in the Tyrols: first description of Tahyna virus in the Alps. Vector Borne Zoonotic Dis. 2014; 14:272-7. http://dx.doi.org/10.1089/vbz.2013.1360

(36.) Kuniholm MH, Wolfe ND, Huang CYH, Mpoudi-Ngole E, Tamoufe U, LeBreton M, et al. Seroprevalence and distribution of Flaviviridae, Togaviridae, and Bunyaviridae arboviral infections in rural Cameroonian adults. Am J Trop Med Hyg. 2006;74:1078-83. http://dx.doi.org/10.4269/ajtmh.2006.74.1078

(37.) Elliott RM. Orthobunyaviruses: recent genetic and structural insights. Nat Rev Microbiol. 2014;12:673-85. http://dx.doi.org/ 10.1038/nrmicro3332

(38.) Blakqori G, Delhaye S, Habjan M, Blair CD, Sanchez-Vargas I, Olson KE, et al. La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts. J Virol. 2007;81:4991-9. http://dx.doi.org/ 10.1128/JVI.01933-06

(39.) Taylor KG, Woods TA, Winkler CW, Carmody AB, Peterson KE. Age-dependent myeloid dendritic cell responses mediate resistance to La Crosse virus-induced neurological disease. J Virol. 2014;88:11070-9. http://dx.doi.org/10.1128/JVI.01866-14

(40.) Bennett RS, Gresko AK, Murphy BR, Whitehead SS. Tahyna virus genetics, infectivity, and immunogenicity in mice and monkeys. Virol J. 2011;8:135. http://dx.doi.org/10.1186/1743-422X-8-135

(41.) Bennett RS, Nelson JT, Gresko AK, Murphy BR, Whitehead SS. The full genome sequence of three strains of Jamestown Canyon virus and their pathogenesis in mice or monkeys. Virol J. 2011;8:136. http://dx.doi.org/10.1186/1743-422X-8-136

(42.) Butchi NB, Woods T, Du M, Morgan TW, Peterson KE. TLR7 and TLR9 trigger distinct neuroinflammatory responses in the CNS. Am J Pathol. 2011;179:783-94. http://dx.doi.org/10.1016/ j.ajpath.2011.04.011

(43.) Winkler CW, Myers LM, Woods TA, Messer RJ, Carmody AB, McNally KL, et al. Adaptive immune responses to Zika virus are important for controlling virus infection and preventing infection in brain and testes. J Immunol. 2017;198:3526-35. http://dx.doi.org/10.4049/jimmunol.1601949

(44.) Bennett RS, Cress CM, Ward JM, Firestone CY, Murphy BR, Whitehead SS. La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys. Virol J. 2008;5:25. http://dx.doi.org/10.1186/1743-422X-5-25

(45.) Winkler CW, Race B, Phillips K, Peterson KE. Capillaries in the olfactory bulb but not the cortex are highly susceptible to virus-induced vascular leak and promote viral neuroinvasion. Acta Neuropathol. 2015;130:233-45. http://dx.doi.org/10.1007/ s00401-015-1433-0

(46.) Winkler CW, Myers LM, Woods TA, Carmody AB, Taylor KG, Peterson KE. Lymphocytes have a role in protection, but not in pathogenesis, during La Crosse Virus infection in mice. J Neuroinflammation. 2017;14:62. http://dx.doi.org/10.1186/ s12974-017-0836-3

Address for correspondence: Karin E. Peterson, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, 903 S 4th St, Hamilton, MT 59840, USA; email: petersonka@niaid.nih.gov

Author affiliation: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA

DOI: https://doi.org/10.3201/eid2504.181016

Caption: Figure 1. Global distribution, phylogenetic relationship, and vectors and hosts of the 5 California serogroup (CSG) viruses included in study of neuropathogenesis. A) These viruses are found across the globe, primarily throughout North America, Europe, Asia, and Africa (1,4,8,10,12-29). Several of these viruses have overlapping regions of distribution (as indicated by diagonal patterns), including in the United States, where LACV, SSHV, and JCV are all present, and Europe, where TAHV and INKV are present. States and countries indicated have evidence of these viruses from reported human cases, serologic surveys of humans and animals, or isolation of virus from mosquitoes. B) Within these closely related CSG viruses, JCV and INKV are the most closely related, followed by LACV and SSHV, and then TAHV (30). The CSG viruses use a variety of mosquito vectors, primarily in the Aedes and Ochlerotatus genera. Listed are the most prominent vectors and additional genera the virus has been found in. Mammals implicated as reservoir or amplifying hosts are listed for each virus; some hosts are shared among several CSG viruses (1,2,12,22,31-33). INKV, Inkoo virus; JCV, Jamestown Canyon virus; LACV, La Crosse virus; SSHV, snowshoe hare virus; TAHV, Tahyna virus.

Caption: Figure 2. Neuroinvasiveness of California serogroup (CSG) viruses in weanling C57BL/6 mice after intraperitoneal inoculation in study of neuropathogenesis. We inoculated 5-15 mice per group with 105 PFU of each virus (A) and 6-13 mice per group with [10.sup.3] PFU of LACV, SSHV, or TAHV (B). Brains and spleens of mice were collected at the experimental endpoint and evaluated for viral RNA by quantitative reverse transcription PCR with virus-specific primers. The average of 3 mock controls is reported for each primer set. The viral RNA level in each sample was calculated as the difference in the percentage in cycle threshold ([C.sub.t]): [C.sub.t] for Gapdh mRNA minus Ct for viral mRNA. Viral RNA was plotted as the percentage of gene expression relative to that of the Gapdh gene. Viral RNA in brains of mice inoculated with [10.sup.5] PFU of each virus (C) or [10.sup.3] PFU of LACV, SSHV, and TAHV (D). Viral RNA in spleens of mice inoculated with [10.sup.5] PFU of each virus (E) or [10.sup.3] PFU of LACV, SSHV, and TAHV (F). Gapdh, glyceraldehyde 3-phosphate dehydrogenase; INKV, Inkoo virus; JCV, Jamestown Canyon virus; LACV, La Crosse virus; SSHV, snowshoe hare virus; TAHV, Tahyna virus.

Caption: Figure 3. Neurovirulence of California serogroup (CSG) viruses in adult, aged, and weanling mice after intranasal inoculation in study of neuropathogenesis. Groups of adult (A, B) and aged (C, D) mice (6-8 mice per group) were inoculated with [10.sup.4] PFU of each virus; groups of adult (E, F) and aged (G, H) mice (6-8 mice per group) were inoculated with [10.sup.2] PFU of LACV, SSHV, TAHV, and JCV; and 5 weanling mice were inoculated with [10.sup.4] PFU of INKV (I, J). E,G) Survival rate differences between adult and aged mice infected with [10.sup.2] PFU of virus were calculated for each virus by using the Gehan-Breslow-Wilcoxon test. LACV was the only virus with a significant difference (p = 0.035). B, D, F, H, J) Viral RNA in mouse brains was analyzed by quantitative reverse transcription PCR with virus-specific primers. The average of 3 mock controls is reported for each primer set. The viral RNA level in each sample was calculated as the difference in the percentage in cycle threshold ([C.sub.t]): [C.sub.t] for Gapdh mRNA minus [C.sub.t] for viral mRNA. Viral RNA was plotted as the percentage of gene expression relative to that of the Gapdh gene. Gapdh, glyceraldehyde 3-phosphate dehydrogenase; INKV, Inkoo virus; JCV, Jamestown Canyon virus; LACV, La Crosse virus; SSHV, snowshoe hare virus; TAHV, Tahyna virus. A color version of this figure is available online (http://wwwnc.cdc.gov/EID/ article/25/4/18-1016-F3.htm).

Caption: Figure 4. Viral antigen in brains of adult and aged mice exhibiting neurologic disease after intranasal inoculation of 104 PFU of California serogroup (CSG) viruses in study of neuropathogenesis. We evaluated [greater than or equal to]4 brains from mice infected with each CSG virus, except INKV (where only 3 brains from mice with neurologic disease were available), for viral immunoreactivity. A, B) Representative images showing distribution of virus (white) and virus merged with Hoechst nuclear stain (blue) via full-section brain scans. Scale bar indicates 1 mm. C) Maximum intensity projections of 5-pm confocal z-stacks (original magnification x63) of brains of mice infected with the indicated CSG virus, labeled for virus (white) and the neuronal marker microtubule-associated protein 2 (MAP2; red). Left panels demonstrate MAP2 staining alone, and right panels are overlays of virus, MAP2, and Hoechst nuclear stain (blue). Yellow arrows indicate the soma of neurons where both viral and MAP2 immunoreactivity are found. Scale bar indicates 10 pm. INKV, Inkoo virus; JCV, Jamestown Canyon virus; LACV, La Crosse virus; SSHV, snowshoe hare virus; TAHV, Tahyna virus.

Caption: Figure 5. Cytotoxicity and viral replication kinetics assays of California serogroup (CSG) viruses in SH-SY5Y cells and human neural stem cells (hNSCs) for up to 96 hours postinoculation in study of neuropathogenesis. SH-SY5Y cells were infected at a multiplicity of infection of 0.1 (A, E, I) or 0.01 (B, F, J), and hNSCs were infected at a multiplicity of infection of 0.01 (C, G, K) or 0.001 (D, H, L). A-D) Confluence was measured over time on the IncuCyte (Essen Bioscience, https://www.essenbioscience.com) as the percentage of the image covered by cells. Graphs show the percentage of confluence compared with that of uninfected control wells. E-H) Cell death was measured over time with the IncuCyte and reported as the total integrated fluorescent intensity of the Cytotox Green (Essen Bioscience) reagent. I-L) Supernatants were harvested from SH-SY5Y cells and hNSCs at 1,6, 12, 24, 48, 72, and 96 hours postinfection and titered on Vero cells by plaque assay. All error bars indicate SEM. PFU, plaque-forming units.
Table 1. Cell death and replication kinetics of 5 encephalitic
California serogroup viruses in SH-SY5Y cells *

                                      MOI 0.1
         Difference in cell death     Virus replication
         ([dagger])
                                        Replication
Virus    Range, hpi   p value range     rate p value
                                      ([double dagger])

LACV        Ref            Ref               Ref
SSHV         NS            NS              0.041#
TAHV         NS            NS               0.110
JCV        61-96      0.047-0.0001         0.033#
INKV       64-96      0.024-0.0001         0.002#

                                             Difference in cell death
                                             ([dagger])

Virus       Peak titer,           hpi        Range, hpi   p value range
               PFU/mL         ([section])

LACV     1.93 x [10.sup.8]         48           Ref            Ref
SSHV      4.36 x [1.sup.9]         72            NS            NS
TAHV     9.13 x [10.sup.7]         48            NS            NS
JCV      1.33 x [10.sup.8]         72          67-96      0.022-0.0001
INKV     8.72 x [10.sup.7]         72          67-96      0.023-0.0001

         MOI 0.01
         Virus replication

           Replication
Virus      rate p value         Peak titer,           hpi
         ([double dagger])         PFU/mL         ([section])

LACV            Ref          3.51 x [10.sup.8]         96
SSHV          0.038#         4.82 x[ 10.sup.9]         72
TAHV           0.995         1.05 x [10.sup.8]         48
JCV           0.034#         1.09 x [10.sup.8]         96
INKV          0.023#         1.55 x [10.sup.8]         96

* All statistical comparisons were made with LACV used as the
reference. hpi, hour postinoculation; INKV, Inkoo virus; JCV,
Jamestown Canyon virus; LACV, La Crosse virus; MOI, multiplicity of
infection; NS, not significant; Ref, referent; SSHV, snowshoe hare
virus; TAHV, Tahyna virus.

([dagger]) Cell death for >3 independent
experiments analyzed by 2-way analysis of variance.

([double dagger]) Replication rates from 3 independent experiments
were analyzed via linear regression analysis of slopes during the
log phase of viral growth (6-48 hpi).

Significant p values (<0.05) are in boldface.

([section]) Time point at which
the sampled peak titer was observed

Note: Significant p values (<0.05) are indicated with #.

Table 2. Cell death and replication kinetics of 5 encephalitic
California serogroup viruses in human neural stem cells *

                 MOI 0.01
        Difference in cell deathfVirus replication

Virus   Range,   p value range     Replication         Peak titer,
         hpi                       rate p value           PFU/mL
                                 ([double dagger])

LACV     Ref          Ref               Ref          3.63 x [10.sup.8]
SSHV    34-49     0.042-0.013         0.018#         4.48 x [10.sup.7]
TAHV    43-61     0.043-0.025          0.050         1.16 x [10.sup.8]
JCV     34-73     0.027-0.003         0.012#         6.42 x [10.sup.6]
INKV    34-79    0.026-0.0001          0.075         1.43 x [10.sup.8]

                                 MOI 0.001
                       Difference in cell death      Virus replication
                               ([dagger])

Virus       hpi        Range,      p value range        Replication
        ([section])      hpi                            rate p value
                                                     ([double dagger])

LACV         48          Ref            Ref                 Ref
SSHV         48         49-94       0.044-0.001            0.091
TAHV         48         64-70       0.047-0.044           0.042 #
JCV          48         58-76       0.037-0.015           0.033 #
INKV         48         46-96      0.045-0.0001           0.035 $

Virus     Peak titer,           hpi
             PFU/mL         ([section])

LACV    1.34 x [10.sup.9]        48
SSHV    3.82 x [10.sup.8]        48
TAHV    1.08 x [10.sup.8]        48
JCV     2.21 x [10.sup.7]        96
INKV    1.30 x [10.sup.8]        96

* All statistical comparisons were made with LACV used as the
reference. hpi, hour postinoculation; INKV, Inkoo virus; JCV,
Jamestown Canyon virus; LACV, La Crosse virus; MOI, multiplicity of
infection; NS, not significant; Ref, referent; SSHV, snowshoe hare
virus; TAHV, Tahyna virus.

([dagger]) Cell death for [greater than or equal to] 3 independent
experiments analyzed by 2-way analysis of variance.

([double dagger]) Replication rates from 3 independent experiments
were analyzed via linear regression analysis of slopes during the
log phase of viral growth (6-48 hpi).

Significant p values (<0.05) are in boldface.

([section]) Time point at which the sampled peak titer was observed.

Note: Significant p values (<0.05) are indicated with #.
COPYRIGHT 2019 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RESEARCH
Author:Evans, Alyssa B.; Winkler, Clayton W.; Peterson, Karin E.
Publication:Emerging Infectious Diseases
Geographic Code:1U9CA
Date:Apr 1, 2019
Words:7284
Previous Article:Symptoms, Sites, and Significance of Mycoplasma genitalium in Men Who Have Sex with Men.
Next Article:Klebsiella pneumoniae ST307 with [bla.sub.OXA-181], South Africa, 2014-2016.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters